WuXi Biologics provides a comprehensive, integrated and highly customizable range of services for the discovery, development and manufacturing of biologics. We are the only open-access biologics technology platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. We provide the world with the ONE true single-source approach that saves our clients critical time and money. Biologics conjugation、Bioprocess CMC、Biosafety、Biologics GMP Manufacturing、Biologics discovery service、Cell Line Development、Formulation Development、Analytical Characterization、Cell Culture and Purification Process Development、Monoclonal Antibodies (mAbs)、vaccine development、vaccine manufacturing、antibody discovery、antibody manufacturing、protein production、analytical services、biotherapeutics、biopharmaceuticals和continuous manufacturing

WuXi Biologics today announced the launch of its innovative technology platform, EffiX™, a proprietary E. coli expression system engineered to deliver high yield and exceptional stability in the production of recombinant proteins and plasmid DNA. 🔔 EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe 🔔 EffiX™ delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA #EffiX #technology #innovation #microbial #recombinantprotein #plasmidDNA #stability For more information, please visit: https://lnkd.in/gZti98vc

Navigating regulatory requirements for animal health products is daunting—but we’ve got your back! 🗂️📋 With our extensive global regulatory filing experience, we support the submission and approval process across USDA, FDA, EMA, and other major agencies. Stay compliant and focused on innovation with our expert guidance. 🌐🐾 https://lnkd.in/eiUh6MzQ #AnimalHealth #RegulatoryAffairs #GlobalFiling #Compliance #WuXiBiologics

Whether you are developing products from mammalian cell culture, microbial fermentation or via in vitro methodologies, choose our Late Stage Development and Commercialization Services to help you meet your critical BLA filing milestones.  Our highly-vetted streamlined development platforms are designed to accelerate your product through all aspects of late phase process, assay and formulation development, optimization, characterization and validation.  Reach out now to redefine and expedite your path to BLA. https://lnkd.in/eDVs8zYe #CellCulture #MicrobialFermentation #ProductDevelopment #LateStageDevelopment #BLA #AssayDevelopment #FormulationDevelopment

Will you be attending BioTrinity (April 1-2) in London? Our team will be onsite and available to discuss your 2025 drug development and manufacturing goals. Contact us and we’ll set up a convenient time to learn about your outsourcing or partnering needs. You may also request a meeting here: https://lnkd.in/gvNFGynY #BioTrinity2025 #DrugDevelopment #PharmaNetworking #BiotechEvents #LondonEvents #PartneringOpportunities

𝗪𝘂𝗫𝗶 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 Ireland: 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 Our Dundalk facility is a world-class hub for biologics manufacturing, innovation, and sustainability. Spanning 26 hectares between Dublin and Belfast, this cutting-edge site is at the forefront of monoclonal antibody (mAb) and recombinant protein production. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 of our Dundalk facility: 🔹 One of the world’s largest single-use bioreactor facilities, featuring 6,000 L perfusion and 48,000 L fed-batch manufacturing suites 🔹 A dedicated team of 770+ professionals driving operational excellence in late-stage clinical and commercial production 🔹 Proudly recognised for excellence in biologics manufacturing. 🔹 Operations began in 2021 🔹 GMP-certified in 2022 🔹 2023 ISPE Facility of the Year Award Winner Brendan McGrath Eimear McCarron Gene Russell Gary Gordon Contact us today to learn more: https://lnkd.in/ew4t4wTi

🌍 Together, We Make a Difference! 💙💚💖💜 At WuXi Biologics Ireland, we are more than just a biologics manufacturing site—we are a team driven by science, purpose, and impact. On Rare Disease Day 2025, we marked this occasion with a special Lunch & Learn session, where our employees came together to learn, engage, and reflect on the difference we make in the lives of rare disease patients. 💡 Did you know? Right here in MFG 6.1 & 6.2, we manufacture a vital treatment for Pompe disease, supporting 50% of patients globally. Behind every product we produce, there is a patient, a family, and a future we help shape. ✨ Thank you to our incredible employees who participated by leaving messages of hope, sharing their voices, and showing solidarity with the rare disease community. Your work matters. Your impact is real. 📸 Join the conversation! Share how you are making a difference and help us spread awareness. Brendan McGrath Xiaoyu Xie Gary Gordon Nicola Boyle Naresh Babu Sama 🔹 #RareDiseaseDay2025 #WuXiBiologicsIreland #PompeDisease #TogetherWeMakeIt #BiologicsForGood #EveryBiologicCanBeMade #CRDMO +

Did you know? 260-450 million people worldwide are suffering from rare diseases. WuXi Biologics firmly believes that curing rare diseases requires both medical breakthroughs and societal compassion! 💪 "My Destiny Is Mine to Command" 💪 Xinxin, Xiaoguo, and Liangliang are scholarship recipients of WuXi Biologics' Rare Disease Education Support Program: ✨Xinxin (Behçet's disease) dreams of becoming a doctor to help others regain health. ✨ Xiaoguo (Pompe disease) refuses to surrender to fate, proving illness can't stop the pursuit of excellence. ✨Liangliang (hereditary optic neuropathy ) lives by the motto: "Though I can't see, there's nothing I can't do." 🤝 WuXi Biologics' Technology Empowerment 🤝 Accelerates R&D and production of rare disease therapies through empowering global biotech partners: 🎇After 11 years of dedication, Pombiliti™ for Pompe disease has brought new hope to patients. 🎇By 2024, dozens of rare disease programs across multiple therapeutic areas are advancing on WuXi Biologics' platform. ❤️ Guardians of Dreams Beyond Laboratories ❤️ 🎇For 4 consecutive years, WuXi Bio has collaborated with Illness Challenge Foundation to provide scholarship to nearly 100 students with rate diseases in China. 🎇On Rare Disease Day 2025, we proudly launched Phase IV of the Education Support Program, awarding scholarships and further assistance to 40 deserving students. #raredisease #technology #platform #CRDMO #education #collaboration

Will you be attending BIO-Europe Spring (March 17-19) in Milan, Italy? If so, let's connect to discuss your 2025 drug development and manufacturing goals. Contact us and we’ll set up a convenient time to learn about your outsourcing or partnering needs. You may also request a meeting here: https://lnkd.in/gvNFGynY #bioeuspring #biotech #biopharma #biomanufacturing #milan #italy

Biologics for pets 🐶💖 PawBio brings WuXi Biologics’ cutting-edge technology, premium quality standards, and integrated CMC to animal health. From the U.S. to China, our globe-spanning network supports drug substance and drug product research, development, and manufacturing to commercialize human-grade care for companion animals. ✔ Integrated technology From concept to commercialization, reduce both the time-to-clinic and project risks with the use of our WuXia™, WuXiUP™, and WuXiUI™ technology platforms. ✔ Effective cost management Unite innovative technology and manufacturing excellence through established processes that increase productivity while decreasing the cost of goods sold (COGS). ✔Global regulatory filing Leverage our experience with regulated authorities worldwide to streamline the registration of your animal health product. ✔ Dual supply sites Advance veterinary medicine in any region and meet the standards of USDA, FDA, EMA, and other global agencies. Learn more: https://lnkd.in/eiUh6MzQ #AnimalHealth #VeterinaryMedicine #DrugDevelopment #ManufacturingExcellence #BiologicsForPets #PawBio

WuXi Biologics today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city. This onsite inspection covered the facilities' quality processes and the entire production system. It concluded without issues, demonstrating the company's robust expertise in meeting global regulatory requirements. #GMP #PMDA #inspection #Japan #quality #compliance For more information, please visit https://lnkd.in/gRDp5Y4T